Currentblue cross blue shield - south dakotaPolicy 07.01.99

Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease (GERD)

Defines coverage and investigational status of transesophageal/transoral endoscopic treatments for gastroesophageal reflux disease (GERD) for Blue Cross Blue Shield – South Dakota members.

Policy Summary

Payerblue cross blue shield - south dakota

PolicyTransesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease (GERD)

Policy CodePolicy 07.01.99

Change TypeNo material changes

Effective DateDec 1, 2010

Next Review Date

Key ActionObtain prior authorization that documents chronic GERD with inadequate control on optimized PPI therapy and hiatal hernia measurements consistent with device/study indications.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalPolicy stance

2 RCTsRCTs cited

≤2 cmHiatal hernia size

≈89%Pooled PPI cessation

2.4%Severe AE rate (TIF)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations and Criteria

Investigational — Not established

Procedures explicitly addressed in this policy are considered investigational:

Investigational procedures: Transoral incisionless fundoplication (EsophyX, EsophyX2, EsophyX2 HD, EsophyXZ, MUSE, GERDX, SRS Endoscopic Stapling System, OverStitch), transesophageal radiofrequency (Stretta), and endoscopic submucosal implantation or injection of prostheses or bulking agents (eg, polymethylmethacrylate beads, zirconium oxide spheres, Durasphere) are considered investigational for the treatment of gastroesophageal reflux disease.

Policy statement

TIF candidate coverage criteria

Covered when ALL of the following are met:

A. Diagnosis: Documented chronic gastroesophageal reflux disease (GERD) with troublesome symptoms

Symptomatic GERD as the indication for therapy (chunks 22,23)

B. Pharmacologic therapy: Inadequate symptom control with optimized proton pump inhibitor (PPI) therapy or patient declines lifelong PPI therapy

Trials and device labeling focused on patients uncontrolled by or seeking alternative to PPIs (chunks 22,23)

C. Anatomic criteria: Hiatal hernia size ≤2 cm (primary TIF trial populations and device intended population); some device labeling/studies include hernias up to 3 cm when concomitant repair is performedhiatal hernia ≤2 cm (preferred); ≤3 cm per expanded labeling/studies

Hiatal hernia size limits per trials and device information (chunks 18,22)

Trial-based eligibility

Evidence in randomized trials included patients with ALL of the following:

Trial-based patient eligibility: Troublesome GERD symptoms despite daily PPI therapy; hiatal hernia ≤2 cm (as enrolled in RESPECT and TEMPO); symptoms including troublesome regurgitation or other atypical symptoms as defined in trial protocols.

Derived from RESPECT and TEMPO trial inclusion criteria.

Reported outcomes and durability

Reported clinical outcomes in studies:

Efficacy outcomes: Randomized trials reported higher rates of elimination of troublesome symptoms with TIF (≈62–67%) versus maximum-dose PPI (≈5%) or sham+PPI (≈45%) for primary symptom endpoints; improvements in GERD-HRQL and high rates of elimination of troublesome regurgitation were reported in follow-up (eg, TEMPO 1–5 year follow-up showing 86–90% elimination of troublesome regurgitation in available patients).

See RESPECT and TEMPO trial results and follow-up data.

Durability and reintervention: Observational registries report durable symptom improvement in many patients up to 5–9 years, with PPI cessation rates varying by study (eg, ≈70% off daily PPI in some registries) but with notable rates of additional/revisional surgery (eg, 22% revisional laparoscopic surgery in one registry).

Bell registry and TEMPO long-term follow-up.

Candidate selection for TIF

TIF considered when ALL of the following are met in the populations studied:

Population and device: Patient has GERD and hiatal hernia ≤3 cm (many studies limited to ≤2 cm) and is anatomically appropriate for the TIF device under consideration (EsophyX, MUSE, GERDX).hiatal hernia ≤3 cm (preferably ≤2 cm)

Device/study population criteria

PPI treatment status: Documentation of prior PPI therapy and response: either symptoms not controlled on PPIs (studies of PPI-uncontrolled patients) or symptoms controlled on PPIs but the patient desires an alternative to lifelong medication (studies of PPI-controlled patients).

PPI treatment context in trials and cohorts

Objective testing documented per study protocols when available (eg, esophageal pH monitoring, DeMeester score, endoscopic esophagitis grading, Hill grade).

Objective measures recommended given inconsistent objective benefits in trials

Evidence summaries

Summary conclusions and applicability

Overall evidence summary for TIF: Randomized trials and observational studies show some subjective benefit for TIF in selected patients, but objective measures (pH normalization, esophagitis) are inconsistently improved and long-term durability beyond 2 years is variable; serious adverse events have been reported.

Evidence synthesis from RCTs, cohorts, and systematic reviews

Overall evidence summary for TERF (Stretta): RCTs and meta-analyses report inconsistent symptom benefit and generally no consistent improvement in objective acid exposure; evidence quality is low to very low with heterogeneity across studies. Larger RCTs with longer follow-up are needed.

Systematic reviews and guideline summaries

Coverage stance based on evidence synthesis

Coverage considerations based on available evidence summaries

TERF (Stretta) coverage considerations: TERF has small RCTs (including sham-controlled trials) that show some symptom improvement but generally not improved esophageal acid exposure; pooled analyses do not demonstrate consistent objective benefit, so TERF should be considered limited/experimental unless high-quality evidence of objective and durable benefit is provided.evidence quality

Interpretation based on RCTs and meta-analyses

Esophageal bulking agents coverage considerations: Evidence for esophageal bulking agents (eg, Durasphere, PMMA beads) is limited to case series without robust objective outcome data; these interventions lack high-quality comparative evidence and should be considered investigational/unproven for GERD.evidence quality

Case series evidence only

Coverage considerations and evidence summaries

Evidence and guideline-derived coverage considerations:

PMMA beads (evidence insufficiency): PMMA bead implantation: evidence limited to a single case series (small sample size) with short or unclear follow-up; lack of long-term safety and effectiveness data precludes coverage endorsement.

Case series evidence (chunk 109)

OverStitch/endoscopic suturing: Endoscopic suturing/plication (OverStitch) evidence consists of a single-arm noncomparative study (n=10) with short follow-up showing symptomatic improvement but lacking control data and objective outcome consistency; durability and comparative effectiveness are unknown.

Single-arm study evidence (chunks 116,117)

Need for high-quality trials: High-quality randomized controlled trials comparing bulking agents, suturing/plication, TIF, and Stretta with sham, optimized medical therapy, and fundoplication using standardized subjective and objective outcomes are needed before broad endorsement of these interventions.

Consensus from evidence review (chunks 109,117)

Evidence-informed considerations (not explicit coverage rules)

Evidence and society guidance to inform coverage decisions:

ASGS position: ASGS (2011) supports transoral fundoplication by trained surgeons for symptomatic chronic GERD in patients who fail to respond to standard PPI therapy or who wish to avoid lifelong medication dependence.

ASGS statement (chunk 126)

Multi-society 2023 guidance - TIF vs fundoplication: Multi-society (2023) consensus suggests fundoplication may be preferred over TIF 2.0 (expert opinion), but TIF 2.0 may be favored over continued PPI in selected patients (conditional, moderate certainty).

Consensus guidance (chunk 127)

Multi-society 2023 guidance - Stretta: Multi-society (2023) guidance suggests fundoplication may be preferred over Stretta (conditional, very low certainty) and that Stretta may be favored over PPI in selected patients (conditional, low certainty).

Consensus guidance (chunk 127)

Use of transesophageal/transoral endoscopic interventions in patients whose symptoms are adequately controlled by medical therapy (proton pump inhibitors) is not supported by the available evidence. Randomized trials and observational studies demonstrate symptomatic benefits in some selected populations, but objective measures of reflux (pH normalization, esophagitis) and long‑term durability are inconsistently improved, and procedure‑related adverse events (including perforation) have been reported. Therefore, these procedures should not be used as substitutes for effective, symptom‑controlling medical therapy in patients who are well controlled on PPIs.

Endoscopic injection/implantation of bulking agents (for example, Durasphere® GR) and use of devices that have been removed from the market or lack adequate supporting evidence are considered investigational. Durasphere® is approved for other indications and its esophageal use is off‑label and described in the document as investigational; the GERDX predicate (NDO) was removed from the market due to complications. Use of off‑label products or devices with documented safety concerns is not supported by high‑quality evidence and is excluded from established coverage.

The clinical trial evidence for transoral incisionless fundoplication (TIF) is primarily limited to patients with hiatal hernias ≤2 cm. Many randomized and comparative studies enrolled only patients with small hernias (≤2 cm), and conclusions about efficacy and safety may not apply to patients with larger hernias or different anatomic indications. Procedures performed outside the populations studied (for example, hiatal hernia >2 cm without documented reduction) may have limited applicability of the trial results.

Early, first‑generation TIF devices (as used in Frazzoni et al. 2011 and similar early series) are no longer available and were found to be considerably inferior to laparoscopic fundoplication in some comparative reports. Because device design and performance have changed across generations, results from first‑generation devices should not be generalized to current devices and contemporary outcomes.

Use of TIF in individuals whose symptoms are adequately controlled by PPIs has insufficient evidence to demonstrate a net health benefit. Randomized trials in PPI‑controlled populations showed improvements in some subjective outcomes but inconsistent or no improvement in objective measures (pH, esophagitis), raising concern for placebo effect and uncertain long‑term reflux control.

Procedures for which the evidence is limited to case series—such as esophageal bulking agents—lack adequate high‑quality comparative data demonstrating objective physiologic improvement or durable clinical benefit. Because these interventions are supported mainly by uncontrolled case series, they are considered investigational and not established treatments.

Interventions supported only by single‑arm case series or small noncomparative studies (for example, PMMA bead implantation or OverStitch suturing in small series) do not provide sufficient evidence of durable objective benefit. Without controlled trials showing sustained physiologic improvement, these procedures should not be considered established therapeutic options.

There is concern that symptomatic improvement after procedures that denervate or otherwise alter sensory perception (for example, radiofrequency denervation/TERF) could mask ongoing pathologic reflux, potentially delaying recognition and treatment of persistent reflux and leading to long‑term complications. This uncertainty about mechanism and long‑term outcomes supports caution in using such techniques without objective evidence of reflux control.

The document does not provide specific, stand‑alone coverage criteria for every listed unlisted or novel transesophageal procedure; many of these interventions require supporting clinical documentation and justification when submitted for coverage. Providers should reference the Codes table and supply objective testing, prior therapy history, and rationale for the selected procedure when requesting authorization.

Current evidence is insufficient to conclude that transesophageal endoscopic therapies as a class improve net health outcomes compared with optimized medical therapy or laparoscopic fundoplication. Trials report some symptomatic benefit in selected patients, but objective outcomes and long‑term durability are inconsistent across modalities (TIF, TERF, suturing, bulking), and adverse events can be serious.

Systematic reviews and meta‑analyses have highlighted evidence limitations and heterogeneity among studies, including differences in patient selection, hiatal hernia size, and endpoints. Many analyses note that procedures were performed in populations not well represented in some trials (for example, patients with larger hernias), which may limit the generalizability of pooled results.

Small comparative studies suggest that earlier, first‑generation EsophyX TIF devices may be less effective than laparoscopic fundoplication. Given these findings from limited comparative data, use of older device generations outside documented trial‑like populations is discouraged pending stronger comparative evidence.

Procedures intended to replace optimized PPI therapy in selected patients should demonstrate durable objective reflux control to be considered equivalent. Some randomized trials showed symptom improvement without sustained pH normalization, indicating that TIF and similar procedures are not uniformly equivalent to optimized PPI therapy or fundoplication.

In patients with well‑controlled GERD on PPIs, the evidence does not support routine use of TIF because objective measures of reflux control and durable benefit are not consistently demonstrated; such use may therefore be considered not medically necessary absent additional compelling indications.

Interventions without evidence of objective physiologic improvement or durable clinical benefit—examples include bulking agents and some TERF reports where only symptom change is shown—lack the data needed to establish effectiveness and therefore remain investigational.

Endoscopic suturing/plication using systems such as OverStitch and implantation of PMMA beads have only limited, uncontrolled data (small single‑arm series) showing short‑term symptom/QOL improvements; controlled trials with objective outcomes and longer follow‑up are required before these techniques can be considered established.

The document emphasizes uncertainty about long‑term outcomes and inconsistent objective efficacy across transesophageal techniques. While many procedures are described and discussed, explicit 'not medically necessary' language for each specific technique is not uniformly stated in the cited sections; instead, the overarching conclusion is that evidence is insufficient for broad endorsement and many procedures remain investigational.

Although the policy delineates investigational status and evidence gaps for listed procedures, the cited sections do not always provide discrete, itemized 'not medically necessary' rules for every procedure. The guidance focuses on the lack of high‑quality randomized comparative evidence, inconsistent objective outcomes, and the need for durable physiologic benefit before routine coverage can be supported.

Provider Responsibilities, Documentation, and Prior Authorization

Note

Contract and coding verification

Prior approval is not applicable for this policy; however, prior authorization is recommended in many situations to verify clinical indications, document prior therapy, and support medical necessity. Providers must consult the Codes table for billing/coding details and verify member benefits and contract language prior to rendering services.

Benefit determinations are based on applicable contract language and member benefits should be verified.
See the Codes table for CPT, HCPCS, revenue, and ICD-10 reporting guidance.
Prior approval (as a formal payer program) is listed as Not applicable, but prior authorization or notification may still be required per contract.

Prior Authorization

Prior authorization to confirm indication

Prior authorization should be used to confirm that the patient meets indication criteria for endoscopic GERD therapies. Authorization requests should document that the patient has chronic GERD with troublesome symptoms despite optimized PPI therapy (or is PPI-dependent and seeking an alternative) and that hiatal hernia size and physiologic testing are consistent with the intended population for the requested procedure.

Procedure, Device, and Regulatory Codes

Codes table referencedmixed

No codes listed

Regulatory 510(k) clearances (FDA)mixed

K160960	510(k) for EsophyX® Z Device with SerosaFuse Fasteners (2016)
K171307	510(k) for EsophyX2 HD and EsophyX Z Devices (June 2017)
K172811	510(k) product specification iterations for EsophyX2 HD and EsophyX Z Devices (Oct 2017)
K240879	510(k) clearance updating instructions for EsophyX (2024)
K120299	510(k) for Medigus SRS Endoscopic Stapling System (MUSE) 2012
K132151	510(k) for MUSE 2014
K233240	510(k) for GERDX-System (2024)
K071553	Predicate NDO Surgical Endoscopic Plication System (2003)

FDA product codesmixed

ODE	FDA product code for EsophyX, MUSE, GERDX (transoral devices)
GEI	FDA product code for Stretta system

Relevant FDA 510(k) & predicate numbersmixed

K160960	EsophyX Z Device with SerosaFuse Fasteners 510(k)
K171307	EsophyX2 HD and EsophyX Z Devices with SerosaFuse fasteners 510(k)
K172811	Additional product specification iterations for EsophyX2 HD and EsophyX Z Devices 510(k)
K240879	2024 FDA 510(k) updating instructions for use and labeling for EsophyX
K120299	MUSE Endoscopic Stapling System 510(k)
K132151	MUSE Endoscopic Stapling System 510(k)
K233240	GERDX-System 510(k)
K071553	Predicate: NDO Surgical Endoscopic Plication System (removed from market)

FDA product codesmixed

ODE	FDA product code for EsophyX and related devices
GEI	FDA product code for Stretta

Procedure and diagnosis codes mentionedmixed

not listed

No CPT/HCPCS/ICD-10 codes are specified in this document section.

No explicit codes in this sectionmixed

No codes listed

Reportable CPT codes and unlisted codesCPT

43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance.
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43212	Esophagoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and dilation and guide wire passage, when performed).
43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance.
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43266	Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and dilation and guide wire passage, when performed).
43499	Unlisted procedure, esophagus.
43659	Unlisted laparoscopy procedure, stomach

Listed and unlisted procedure CPT codesCPT

43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance.
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43212	Esophagoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and dilation and guide wire passage, when performed).
43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance.
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43266	Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and dilation and guide wire passage, when performed).
43499	Unlisted procedure, esophagus.
43659	Unlisted laparoscopy procedure, stomach
43999	Unlisted procedure, stomach.

HCPCS / OtherHCPCS

No code(s)

Hiatal hernia size (primary TIF population)

Hiatal hernia size (primary TIF indication)≤ 2 cm

GERDX manufacturer website noteManufacturer notes use with hiatal hernia up to 3 cm

Device labeling contextEsophyX 2016 clearance cited reduction of hiatal hernias of 2 cm or less; later clearances allowed repair to ≤2 cm

pH normalization threshold

pH normalization metric

Definitions and Background

GERD is common, affecting approximately one in five adults, and is characterized by reflux‑related symptoms and potential complications such as erosive esophagitis and Barrett esophagus. Standard management emphasizes conservative measures and proton pump inhibitors, with laparoscopic Nissen fundoplication remaining the established surgical option for refractory disease; minimally invasive transesophageal/endoscopic therapies are being investigated as alternatives in selected patients.

Transesophageal endoscopic therapies

DefinitionMinimally invasive endoscopic approaches for GERD including transoral incisionless fundoplication (TIF/gastroplication), radiofrequency energy application (Stretta), endoscopic suturing/plication, and injection/implantation of prosthetic or bulking agents.

PurposeProvide alternative to open or laparoscopic fundoplication or chronic medical therapy.

ExamplesTIF, Stretta, OverStitch, bulking agents (Durasphere, PMMA beads)

TIF (Transoral Incisionless Fundoplication)

Policy Summary

Payerblue cross blue shield - south dakota

PolicyTransesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease (GERD)

Policy CodePolicy 07.01.99

Change TypeNo material changes

Effective DateDec 1, 2010

Next Review Date

Key ActionObtain prior authorization that documents chronic GERD with inadequate control on optimized PPI therapy and hiatal hernia measurements consistent with device/study indications.

SourceLink

On This Page

Guideline positions: Society guidance varies: ACG suggests conditional consideration of TIF in selected patients without severe esophagitis or large hernia and does not recommend Stretta; multi-society 2023 guidance suggests fundoplication may be preferred over TIF or Stretta but also suggests TIF or Stretta may be favored over continued PPI in selected patients (conditional, low–moderate certainty).

Guideline excerpts (chunks 123,127)

NICE conclusions: NICE (2013) concluded short- and medium-term safety of endoscopic radiofrequency is adequate but long-term outcomes are uncertain; symptomatic relief is reported but objective reflux reduction is inconclusive, with concern that denervation could mask ongoing reflux.

NICE guidance (chunk 128)

Document diagnosis of chronic GERD and specify hiatal hernia size (e.g., ≤2 cm or ≤3 cm as relevant to device/indication).
Document optimization and escalation of PPI therapy with dates, doses, and response.
Include objective testing when available (eg, esophageal pH/pH-impedance monitoring, DeMeester score, endoscopy findings).

Prior Authorization

Prior authorization recommended

Prior authorization is recommended when evidence is limited, when there is potential safety risk, or when patient selection differs from trial populations. When requested, authorization should confirm refractory symptoms despite optimized PPI therapy and document rationale for endoscopic therapy versus continued medical therapy or surgical fundoplication.

Authorization should confirm trial of optimized PPI therapy and reasons for considering endoscopic approach.
When hiatal hernia exceeds device-labeled size (eg, >2 cm for primary TIF trials or >3 cm for some device reports), note that evidence and device generation may not support use.
Prior authorization may be required for transesophageal endoscopic procedures per payer contract.

Billing Rule

Code reporting and potential prior authorization

Providers must report appropriate CPT, HCPCS, revenue, and ICD diagnosis codes when billing for endoscopic GERD procedures. Some procedures may be reported with unlisted procedure codes; reporting must include operative notes and documentation to support medical necessity. Prior authorization may be required depending on payer rules.

Use appropriate established CPT codes where available (eg, 43210, 43257) or unlisted codes (eg, 43499, 43659, 43999) when applicable.
When using unlisted codes, submit operative reports, device identifiers, and clinical rationale with the claim.
Revenue and place-of-service codes should reflect inpatient vs outpatient setting per service.

Denial Risk

Investigational therapies — denial risk

Claims for procedures considered investigational by this policy (including transoral incisionless fundoplication, transesophageal radiofrequency/Stretta, and endoscopic submucosal implantation/injection of bulking agents) are at risk of denial. Authorization requests and claims lacking documentation that aligns with evidence-based indications or contract language may be denied.

TIF (EsophyX, MUSE, GERDX, etc.), Stretta, and endoscopic bulking procedures are considered investigational for GERD in this policy.
Claims may be denied if billed with codes describing investigational procedures without supportive documentation meeting medical necessity criteria.
Submit full clinical records and rationale if requesting exception or review.

Documentation Required

Patient selection and device generation

Patient selection should match populations studied and device labeling. Use of TIF or other endoscopic devices outside the population or with older device generations may affect expected outcomes and coverage decisions.

TIF evidence and device labeling primarily address patients with hiatal hernia ≤2 cm (some studies and device labeling include up to 3 cm); procedures in larger hernias were generally excluded from trials.
Patients with abnormal esophageal motility or other contraindications in trial protocols may not be appropriate candidates.
Device generation matters: earlier-generation devices had different outcomes; document device model/version where applicable.

Note

Long-term outcome uncertainty

There is uncertainty about long-term durability of symptom relief and objective control of reflux for endoscopic GERD therapies. Longer-term outcomes may show decreased efficacy and instances where symptom improvement does not correlate with normalization of esophageal acid exposure.

Observational follow-up indicates some loss of efficacy over time and recurrence of hiatal hernia in subsets of patients.
NICE and other bodies have noted uncertainty about longer-term outcomes and potential for symptom improvement without objective reflux control.
Document counseling provided to patients regarding uncertain long-term benefits and potential need for subsequent surgical intervention.

Denial Risk

Claims may be denied if billed with code

Claims may be denied if billed with codes that do not match the documented procedure, or if investigational procedures are billed without clinical justification. Use the Codes table and provide supporting documentation for unlisted codes to avoid denials.

Do not bill investigational procedures as standard, covered services without prior authorization and supporting documentation.
When using unlisted CPT codes (eg, 43499, 43659, 43999), include operative notes, device details, and medical necessity justification with the claim.
Mismatched or insufficient coding and documentation can result in claim denial or request for additional information.

Documentation Required

Suggested documentation to support medical necessity

Suggested documentation to support medical necessity for authorization and claims includes a clear clinical history of GERD, objective testing results when available, detailed record of prior medical therapy and responses, hiatal hernia measurements, and rationale for choosing endoscopic therapy over medical or surgical alternatives.

Document chronicity of GERD symptoms, severity (eg, GERD-HRQL, RDQ, RSI), and impact on quality of life.
Include prior PPI therapy details: agents, doses, duration, adherence, and response; note any PPI-refractory or PPI-dependent status.
Provide objective testing: endoscopy findings (esophagitis, Barrett's), pH or pH-impedance monitoring results (DeMeester score), manometry if relevant, and hiatal hernia size/grade.
Attach operative reports, device identifiers, and follow-up plans when submitting unlisted code claims.

Documentation Required

Clinical rationale and prior therapy

Clinical rationale and documentation of prior therapy should explain why endoscopic therapy is being considered (eg, inadequate response to optimized PPI therapy, desire to avoid lifelong medication, contraindication to or preference against fundoplication), and reference relevant guideline recommendations when applicable.

Note discussions with the patient regarding alternatives (continued PPI therapy, laparoscopic fundoplication) and why those were not chosen.
Include any specialist consultations, risk-benefit counseling, and informed consent reflecting the investigational or limited-evidence nature of the procedure.
Reference society guidance or device labeling that supports the chosen approach where relevant.

Step Therapy

Conservative therapy emphasized

Conservative therapy is emphasized as the initial approach for GERD. Lifestyle modifications and optimization of PPI therapy should be attempted and documented before considering endoscopic interventions.

Lifestyle measures: weight loss, smoking cessation, head-of-bed elevation, and elimination of food triggers.
PPIs are the most effective medical therapy; document trial and optimization as prerequisite unless contraindicated.
Surgical fundoplication remains the established operative comparator when surgical repair is indicated.

Step Therapy

Medical therapy prerequisite / Step therapy context

Medical therapy prerequisite and step therapy context: evidence selection and trial inclusion criteria focused on patients uncontrolled by PPIs or those controlled but seeking alternatives. Providers should document prior PPI use and inadequate response or patient preference that justifies consideration of endoscopic therapy after standard medical management.

Patients in RCTs generally had persistent troublesome symptoms despite daily PPI therapy; some trials included PPI-controlled patients seeking an alternative to lifelong therapy.
Step therapy expectation: document optimized PPI therapy (dose escalation, adherence) and any trials of alternative medical strategies prior to authorization.
Consideration of fundoplication should be documented when appropriate; endoscopic therapies were generally studied against PPI therapy and not always directly compared with fundoplication.

Percent total recorded time with esophageal pH <4

Threshold for normality5.3% of total recorded time pH <4

ContextUsed in RCTs as definition of pH normalization

Hiatal hernia size (study populations)

Hiatal hernia size (studies/intended population)≤ 3 cm

Many studies limited to≤ 2 cm

Study contextTIF evaluated as alternative in patients with hiatal hernias ≤3 cm controlled by PPIs; primary evidence focused on ≤2 cm

Procedure descriptionEndoscopic transesophageal procedure (e.g., EsophyX, MUSE) to create a fundoplication or full-thickness plication of the gastroesophageal junction.

DevicesExamples include EsophyX/EsophyX2, MUSE, GERDX

Intended effectRecreate a valve/barrier to reflux by folding and fastening the gastric fundus endoscopically.

GERDX-System

Regulatory statusGERDX-System cleared via 510(k) (K233240, 2024)

Intended useEndoscopic full-thickness plication for chronic GERD in individuals who require and respond to pharmacologic therapy

Manufacturer noteWebsite describes use with hiatal hernia up to 3 cm

Stretta

DefinitionAn electrosurgical/coagulation device (Stretta) used to deliver radiofrequency energy to the gastroesophageal junction to treat GERD.

MechanismRF energy creates submucosal thermal lesions; proposed effects include denervation and tissue tightening from collagen contraction/fibrosis.

Regulatory noteStretta system cleared by FDA (product code GEI); available for treatment of GERD

TIF (abbreviation)

AbbreviationTIF = Transoral incisionless fundoplication

ContextTIF refers to endoscopic fundoplication procedures to reconstruct the gastroesophageal valve

Devices referencedEsophyX, MUSE, GERDX (TIF 2.0 for later-generation techniques)

PPI (abbreviation and context)

AbbreviationPPI = Proton pump inhibitor

RoleStandard initial medical therapy for GERD; trials often enrolled patients uncontrolled on or dependent on PPIs

Clinical contextPPI response status is used in selecting candidates for endoscopic therapies

Troublesome symptoms (trial definition)

DefinitionTroublesome symptoms defined in trials as mild symptoms occurring ≥2 days/week or moderate-to-severe symptoms occurring >1 day/week

Use as outcomePrimary outcome in TEMPO and RESPECT trials included elimination of daily troublesome regurgitation and atypical symptoms

RelevanceUsed to determine symptomatic eligibility and primary endpoints in RCTs of TIF

TIF — procedure and outcomes

Procedure summaryTIF (endoscopic fundoplication with devices such as EsophyX, MUSE, GERDX) aims to reduce reflux by creating a fundoplication endoscopically.

Outcome contextObserved outcomes include symptom improvement, PPI discontinuation, and variable objective pH/DeMeester score changes in cohorts and trials.

Durability notesLong-term observational studies report durability up to 5–9 years in some series but with variable reintervention rates

Normalized pH

DefinitionNormalized pH = percent time with esophageal pH <4 below the defined threshold

Common threshold citedOften <4% (for ≤4.2% recording time) in some trial definitions; other definitions used 5.3% as threshold for normality in RCTs

Use in studiesObjective acid exposure normalization used as physiologic outcome though results inconsistent across trials

Stretta — intent and evidence context

DefinitionStretta: endoscopic radiofrequency energy therapy delivering thermal energy to the gastroesophageal junction to reduce GERD symptoms

Evidence summaryRCTs and meta-analyses show inconsistent objective acid exposure improvement despite some symptom relief; NICE noted short/medium-term safety but uncertain long-term outcomes

Mechanistic cautionSymptom improvement may reflect denervation rather than reflux control, raising long-term monitoring concerns

TIF / EsophyX2 / MUSE

Devices/techniquesEsophyX2, MUSE, GERDX — device-based transoral fundoplication systems used to create an endoscopic fundoplication

Comparative contextLater-generation TIF (TIF 2.0) devices evaluated in RCTs and cohorts with outcomes compared to PPI therapy and sometimes fundoplication

Safety notePerforations and serious adverse events reported in some device series (eg, MUSE perforations in Testoni 2022)

Esophageal bulking agents

DefinitionEsophageal bulking agents: injectable materials (e.g., Durasphere, PMMA beads) placed at the gastroesophageal junction to bulk the LES region

Evidence levelEvidence limited to small case series and pilot studies; RCTs lacking or terminated for lack of efficacy

Regulatory/Off-label noteDurasphere is approved for urinary/fecal incontinence; use for GERD is off-label/investigational

Transesophageal endoscopic suturing and plication

DefinitionEndoscopic suturing/plication involves placement of sutures or plications at the gastroesophageal junction (eg, OverStitch, GERDX) to augment the GEJ.

EvidenceEvidence includes single-arm studies and small series; durability and objective physiologic benefit not well established

Clinical roleInvestigational pending higher-quality comparative trials

Polymethylmethacrylate (PMMA) beads

MaterialPolymethylmethacrylate (PMMA) beads used for submucosal implantation at GEJ

EvidenceSingle case series (Feretis 2001) with small sample and limited follow-up; insufficient to establish efficacy or durability

StatusConsidered investigational/unproven in this document

Stretta — procedural summary

Stretta summaryEndoscopic RF procedure applying thermal energy to the GEJ to create submucosal lesions intended to reduce reflux symptoms

Evidence cautionSymptom improvements seen but objective pH improvements inconsistent; long-term outcomes uncertain per NICE

Recommendation contextMany societies provide conditional guidance; use in selected patients only

TIF 2.0

TIF 2.0Later-generation transoral incisionless fundoplication intended to reconstruct the gastroesophageal valve endoscopically

OutcomesObserved symptom/QoL improvements and PPI discontinuation in cohorts; objective acid exposure improvements inconsistent

DurabilityLong-term cohort data report mixed durability and some need for revisional surgery